PMID- 25953424
OWN - NLM
STAT- MEDLINE
DCOM- 20160128
LR  - 20220310
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 15
DP  - 2015 May 8
TI  - The prognostic value of EGFR overexpression and amplification in Esophageal 
      squamous cell Carcinoma.
PG  - 377
LID - 10.1186/s12885-015-1393-8 [doi]
LID - 377
AB  - BACKGROUND: In view of the prominent role in cancer cell biology and alteration 
      in substantial numbers of ESCC, defining EGFR molecular characteristics relevant 
      to patient prognosis is of great importance. Therefore, we analyzed the protein 
      expression and gene copy variation of the epithelial growth factor receptor 
      (EGFR) in Chinese esophageal squamous cell carcinoma (ESCC) and explored the 
      possible associations with various features of the tumors and survival of the 
      patients. METHODS: Sections were made from tissue microarray composed of 96 ESCC, 
      and examined for EGFR expression by means of immunohistochemistry (IHC) and for 
      EGFR gene amplification by means of fluorescence in situ hybridization (FISH). 
      The results of IHC were evaluated with six different reported scoring systems. 
      Correlation with clinical features and survival was evaluated using chi-square 
      test and Kaplan-Meier analysis. RESULTS: EGFR overexpression according to scoring 
      system 1 significantly correlated with advanced lymph node involvement (P = 
      0.046), patient disease specific free survival (DFS) (P = 0.006) and overall 
      survival (OS) (P = 0.007). No such association was observed using other 5 scoring 
      systems (P > 0.05 ). EGFR amplification was associated with lymph node metastasis 
      (P = 0.028), but not correlated with DFS and OS until 20 months. CONCLUSIONS: 
      EGFR IHC overexpression evaluated by scoring system 1 might be suitable to be 
      used in predicting patients survival in ESCC. EGFR gene amplification showed 
      delayed prognostic information after 20 months.
FAU - Jiang, Dongxian
AU  - Jiang D
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. jiangdongxian3@aliyun.com.
FAU - Li, Xiaojing
AU  - Li X
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. li.xiaojing@zs-hospital.sh.cn.
FAU - Wang, Haixing
AU  - Wang H
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. wang.haixing@zs-hospital.sh.cn.
FAU - Shi, Yuan
AU  - Shi Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. shi.yuan@zs-hospital.sh.cn.
FAU - Xu, Chen
AU  - Xu C
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. xu.chen@zs-hospital.sh.cn.
FAU - Lu, Shaohua
AU  - Lu S
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. lu.shaohua@zs-hospital.sh.cn.
FAU - Huang, Jie
AU  - Huang J
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. huang.jie@zs-hospital.sh.cn.
FAU - Xu, Yifan
AU  - Xu Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. xu.yifan@zs-hospital.sh.cn.
FAU - Zeng, Haiying
AU  - Zeng H
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. zeng.haiying@zs-hospital.sh.cn.
FAU - Su, Jieakesu
AU  - Su J
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. su.jieakesu@zs-hospital.sh.cn.
FAU - Hou, Yingyong
AU  - Hou Y
AD  - Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, 
      People's Republic of China. houyingyong@hotmail.com.
FAU - Tan, Lijie
AU  - Tan L
AD  - Department of Thorax Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      200032, People's Republic of China. tan.lijie@zs-hospital.sh.cn.
LA  - eng
PT  - Journal Article
DEP - 20150508
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*biosynthesis/genetics
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - Disease-Free Survival
MH  - ErbB Receptors/*biosynthesis/genetics
MH  - Esophageal Neoplasms/*genetics/pathology
MH  - Esophageal Squamous Cell Carcinoma
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - *Prognosis
PMC - PMC4437683
EDAT- 2015/05/09 06:00
MHDA- 2016/01/29 06:00
PMCR- 2015/05/08
CRDT- 2015/05/09 06:00
PHST- 2015/02/05 00:00 [received]
PHST- 2015/04/29 00:00 [accepted]
PHST- 2015/05/09 06:00 [entrez]
PHST- 2015/05/09 06:00 [pubmed]
PHST- 2016/01/29 06:00 [medline]
PHST- 2015/05/08 00:00 [pmc-release]
AID - 10.1186/s12885-015-1393-8 [pii]
AID - 1393 [pii]
AID - 10.1186/s12885-015-1393-8 [doi]
PST - epublish
SO  - BMC Cancer. 2015 May 8;15:377. doi: 10.1186/s12885-015-1393-8.